Going to Global, Gathering Towards the Future! China Biologics Going Global Forum 2025 Successfully Held

On July 2nd, the "China Biologics Going Global Forum 2025" was successfully held in Shanghai, with the theme of "Going Global, Gathering Towards the Future", which was co-hosted by Chime Biologics, HYqure Biotech, Alioth Biotech, Medium Bank, and NanoMicro. At the forum, several executives from multinational pharmaceutical companies, opinion leaders from local innovative pharmaceutical companies, core suppliers of the industry chain and representatives from top investment institutions gathered together to have an in-depth dialogue on the strategic choices, commercialization path and ecological synergy of China's biopharmaceuticals' international development through a number of exciting keynote speeches and panel discussions.

Decoding the globalization of biologics in China: Strategy-Practice-Innovation-Regulation

Minrong Zhang, Chairman of the Board of Directors of United Investment Europe Co., Ltd, pointed out in her opening speech that Chinese biopharmaceutical enterprises are ushering in a golden window of "innovation going global" at a time when the global biopharmaceutical industry is undergoing profound changes. With the theme of " Going to the Global, Gathering Towards the Future ", the forum will bring together executives from multinational pharmaceutical companies, local innovation leaders, core suppliers of the industry chain, and top investment institutions to engage in an in depth dialogue on strategic choices, capital empowerment, and ecological synergies, with the aim of pooling wisdom from the whole industry chain, and cracking the common problems of technological barriers, regulatory differences, and market access . The aim of the dialogue is to gather the wisdom of the whole industry chain, to solve the problems of technical barriers, regulatory differences and market access, to jointly explore the path of China's biopharmaceuticals from "local innovation" to "global value", and to write a new chapter in the globalization of China's biopharmaceutical industry.

Yingfei Fu, Managing Director of The Boston Consulting Group, presented on the topic of "Options and Strategies for Chinese Biopharmaceutical Innovations to Go Global", systematically dismantling the logic of going overseas. Currently, the international development of Chinese pharmaceutical enterprises is mainly driven by several major internal and external driving forces, such as the enhancement of domestic innovative drug research and development results, the increasing pressure of price reduction in the domestic market, and the huge potential of overseas market development. In this process, China's biopharmaceuticals have shown three significant features - the globalization process has been significantly accelerated, the innovation and international competitiveness of overseas products have been significantly enhanced, and the market coverage has been continuously expanded. However, there are many challenges such as technical barriers, regulatory differences and cultural adaptation. The key to break through lies in the importance of differentiated products, solid clinical and registration capabilities, suitable commercialization models and international talent pool.

Ke Shao, Deputy General Manager of Kexing Biopharm, shared the cooperation case based on the global commercialization of Kexing Biopharm .He pointed out that China's local pharmaceutical enterprises are "blossoming" and "competing to go global", with many innovative achievements on par with international standards, and have accumulated a certain foundation for going to sea in terms of talent, flexible business model, clinical research quality and other aspects .In addition to the increasingly fierce domestic competition, Chinese pharmaceutical companies are accelerating the pace of international transformation .To this end, enterprises should choose the most suitable mode of going to sea according to their own characteristics, whether it is going to sea on their own, borrowing a ship to go to sea or comprehensive localization, the key lies in finding the most suitable development path. As one of the earliest biopharmaceutical enterprises to implement globalization strategy in China, Kexing Biopharm has built up a perfect global business network through years of practice, and its international product selection has adhered to the criteria of "high technology content, high market value, high registration standard and rapid commercialization", which has provided the industry with valuable practical experience.

Jimmy Wei, President of Chime Biologics. In his keynote speech entitled "Emerging Powerhouse: How China's Efficient Collaborative Innovation is Reshaping the Global Biopharmaceutical Landscape", discussed the development path of China's biopharmaceutical industry to achieve global breakthroughs through collaborative innovation. Against the backdrop of profound changes in the global biopharmaceutical industry, Chinese biopharmaceutical companies are facing the dual challenges of capital efficiency and innovation efficiency. On the one hand, the international capital market is increasingly demanding higher return on investment in biopharmaceuticals; on the other hand, the intensified competition in the industry is forcing companies to continue to improve their innovation efficiency. Jimmy Wei particularly emphasized that efficiency is becoming the key to determine the success or failure of enterprises in the new round of global biopharmaceutical competition. To continuously improve efficiency, it is important to focus on three interconnected core elements: regulatory policy, talent, and local R&D infrastructure. With the synergistic strengthening of these three elements, Chinese biopharmaceutical companies will be able to better demonstrate their strengths and development potential on the global stage.

Yushan Bai, a consultant from the Regulatory Affairs and Strategic Planning Department of HiRO, explained the overseas regulations and policies of the Japanese and Korean pharmaceutical markets. She analyzed the unique advantages of the Japanese pharmaceutical market, pointing out that Japan is the fourth largest pharmaceutical market in the world, and its market position has been established thanks to the high-quality clinical trial system, clinical data recognized by international authorities such as FDA and EMA. Currently, in order to encourage pharmaceutical innovation, Japan provides R&D companies and researchers with diversified policy support programs, including accelerated review and priority review, which have significantly improved the approval efficiency of new drug development and launch. In the Korean market, Yushan Bai highlighted the country's core competencies as an international clinical trial destination. With its highly developed healthcare infrastructure, world-class medical equipment and high level of medical professionals, combined with a more than adequate subject population and strong government support, South Korea has gradually gained a significant position in the global pharmaceutical R&D arena.

The Chime Innovation Alliance made its domestic debut: Creating a New Ecology for Biological Drugs Going Overseas

The forum ushered in the highlight moment - the official launch of Chime Innovation Alliance. Chime Innovation Alliance was initiated by Chime Bio together with partners from upstream and downstream of the industry chain. With the core concept of "collaborative innovation and global empowerment", the Alliance integrates the resources of the whole chain such as CRDMO, high-end equipment, key reagents and consumables, and creates a one-stop, high-efficiency and low-cost solution for globalization of biopharmaceuticals. At the launching ceremony, representatives of the alliance members, including HYqure Biotech, Alioth Biotech, MediumBank and NanoMicro, joined hands on the stage and lit up the alliance logo, symbolizing "Gathering Strength to Go Global". This marks the first time that China's biopharmaceutical industry has reorganized dispersed innovation elements into a synergistic network in a systematic and ecological way to provide global customers with full life-cycle support from early R&D to commercial production. Localization

Panel Discussion: Unlocking the Golden Key to Chinese Biologics Globalization

In the roundtable dialogue on "BD Strategies and Global Collaboration Opportunities for Biologics Going Global", Jimmy Wei, President of Chime Biologics, together with Ke Shao, Deputy General Manager of Kexing Biopharm, Yanshan Huang, Founder and CEO of Doer Biologics, and Sofie Qiao, CEO of Vivace Therapeutics & Virtuoso Therapeutics. Rulei Chen, Co-Founder and COO of Innolake Biopharm, engaged in an in-depth dialogue. The guests agreed that in the face of global competition, it is difficult to break through alone, and the only way to turn China's clinical execution speed and cost advantages into global competitiveness is to integrate R&D, capital and commercialization resources through industrial alliances, and to select manufacturing partners with international standards. They stressed that start-ups need to balance the pace of innovation and financing, and mature companies should accelerate the establishment of international commercialization capabilities, only through a two-wheel drive can they win broad space in overseas markets.

The Panel Discussion on "Capital Helps Biopharmaceutical Innovation to Go Global: VC's Perspective and Strategy" was moderated by Siyuan Wang, Vice President of Strategic Development of Chime Biologics, with the participation of  Diana Qian, Partner of Cathay Sanofi Capital, Viva He, Managing Director of AstraZeneca-CICC Healthcare Capital, Jie Chen, Founding Partner of Yuanbio Venture Capital, and David Xu, Managing Partner of Mingxin Capital. The investors pointed out that VCs are upgrading from financial investors to strategic partners, prying enterprises to go overseas with the triple leverage of capital, resources and global network. They admitted that China's biopharmaceutical assets have become popular targets for cross-border M&A and License-out by virtue of the advantages of R&D speed, cost-effectiveness and talent reserve; in the future, capital will pay more attention to data quality, compliance standards and geopolitical risks, forcing enterprises to polish their core competitiveness with global standards.

The Panel Discussion on "Building Biologics Innovation Alliance and Ecosystem: The Power of Collaboration to Go Global" was moderated by Xiangying Zhu, CEO of HYqure Biotech.Representatives of the alliance members, including Liqiang Hua, Co-CEO of MediumBank, Biwang Jiang, Founder and Director of NanoMicro, Qijun Jia, Founder and Chairman of Alioth Biotech, and Guozhen Xing, CEO of ZSHK Laboratorise Limited and General Manager of Anlingbio, pointed out that local supply chain enterprises are accelerating the import substitution of key raw materials and equipment, and innovative drug companies are competing with international giants in the areas of target discovery, molecular design and other cutting-edge fields. Innovative drug enterprises are competing with international giants in frontier areas such as target discovery and molecular design, and their technological confidence has increased significantly. They believe that by integrating non-clinical evaluation, process validation and other professional services through the platform of “Chime Innovation Alliance”, and by winning the recognition of international customers with "China's efficiency + global standards", China's biopharmaceutical industry will eventually achieve the goal of moving from "clinical evaluation" to "global standard". single-point breakthrough" to "ecological overseas" qualitative leap.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring its partners' success in delivering innovative biologics to the world. Chime Biologics is a biologics service provider, from pre-clinical support and cell line development to clinical and commercial manufacturing of DS and DP. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the global biologics industry. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling our commitment to human health. For more information, please visit www.chimebiologics.com

About Chime Innovation Alliance

The Chime Innovation Alliance is dedicated to being an enabler and accelerator of global biopharmaceutical innovation. The alliance integrates the rapidly growing Chinese biopharmaceutical innovation ecosystem and provides globally leading innovative, efficient, and cost-effective solutions for the research and development and production of large-molecule drugs worldwide. It promotes the innovative transformation of the global pharmaceutical industry and benefits patients globally.